reported to be associated with the high incidence of adverse events. 9 Among them, the most common serious adverse event was leukopenia. 9, 10 Predictors that forecast the risk of leukopenia may be of great value for drug monitoring.
Till now, thiopurine S-methyltransferase (TPMT) is still the most widely accepted predictor for leukopenia and the current guidelines have recommended TPMT genotyping before thiopurines treatment. 11 Although about 20% of patients who experience leukopenia can be explained with genetic variants in TPMT, 12 a majority of patients inherited wild-type genotypes still developed leukopenia. [13] [14] [15] Moreover, the frequency of the TPMT polymorphisms was considerably lower in Asians (around 1%) than in populations of European descent. 13, 15, 16 Although thiopurine-induced leukopenia is more common in East Asians including Chinese, Japanese, and Koreans compared with Caucasians, 17, 18 suggesting the contribution of unknown genetic background responsible for thiopurine sensitivity. Recent studies reported the novel gene NUDT15 c.415C.T variant (rs116855232) was significantly associated with thiopurine-induced leukopenia in Asian patients with IBD. [19] [20] [21] Our previous single-center study has first confirmed it in Chinese patients with IBD. 19 However, the sample size was small. Meanwhile, Mariyama et al 22 have identified other 3 NUDT15 coding variants (c.416G.A, c.36_37insGGAGTC, and c.52G.A) resulting in 74.4% to 100% loss of nucleotide diphosphatase activity and associated with thiopurine intolerance in children with acute lymphoblastic leukemia, which have not identified in patients with IBD.
Meanwhile, the impact of multiple NUDT15 variants on Chinese patients with IBD has not been reported. Considering the low frequency of variant of c.416G.A (0.2%), we conducted this multicenter study to further confirm the NUDT15 c.415C.T and 2 newly discovered variant (c.36_37insGGAGTC and c.52G.A) genotypes on thiopurine-induced leukopenia in Chinese patients with IBD.
MATERIALS AND METHODS

Patients and Treatment
Consecutive patients with IBD prescribed thiopurines for more than 2 weeks were recruited in 4 tertiary hospitals in different areas of China from July 1, 2012 to November 30, 2015. The self-reported ethnicities of all patients were Chinese Han. This cohort is different from our previous single-center study. 19 The diagnosis of IBD was according to the current guidelines 3 based on clinical, endoscopic, histopathological, radiological, and/or surgical findings. Patients without blood samples or intact clinical data were excluded. Dosage adjustment of thiopurines was according to white blood cell count and other adverse events. The target maintenance dosage was 2 mg/kg daily for AZA and 1 mg/kg daily for mercaptopurines. Two milliliter Peripheral venous blood samples (EDTA anticoagulation) were obtained for genotype analysis. The present study was approved by the Ethics Committee of the Sixth Affiliated Hospital of the Sun Yat-sen University.
Genotyping
Total genomic DNA was extracted from peripheral blood using the QIAamp DNeasy Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Phenotypes of NUDT15 c.36_37insGGAGTC (rs554405994) and c.52G.A (rs186364861) was determined by allele-specific polymerase chain reaction and sequencing. The sequences of the forward and reverse primers for c.36_37insGGAGTC and c.52G.A were 5-TTACAGCGAAACTCTAAGGC-3, 5-TGGGGGATACATTAAGAGACTGC-3. All polymerase chain reactions were performed in a 20 mL reaction mixture consisting of ABI buffer, dNTPs (0.2 mM/each), primer 10 mmol, DNA 2 mL, Taq DNA polymerase 0.2 mL. Polymerase chain reaction amplification starts with an initial denaturation at 948C for 5 minutes, continued with 30 cycles of 948C for 60 seconds, 528C for 30 seconds and 728C for 30 seconds. Final extension was performed at 728C for 10 minutes. The methods to determine the frequency of NUDT15 c.415C.T and TPMT mutant alleles (TPMT*2, TPMT*3A, TPMT*3B, and TPMT*3C) (rs1800462, rs100460, and rs1142345) were described as previously. 19 
Data Collection and Follow-Up
Clinical data were retrospectively collected from IBD databases from 4 centers, including the Sixth Affiliated Hospital of Sun Yat-sen University, Sir Run Run Shaw Hospital, Peking Union Medical College Hospital and Xijing Hospital. White blood cell count ,3500 mm 23 was defined as leukopenia, which was graded by common toxicity criteria as follows: grade 1, 3000 to 3500 mm 23 ; grade 2, 2000 to 3000 mm 23 ; grade 3, 1000 to 2000 mm 23 ; and grade 4, ,1000 mm 23 . Leukopenia happened within 8 weeks, 8 to 24 weeks, and more than 24 weeks were defined as early, middle, and late leukopenia, respectively. Other adverse events included severe hair loss (defined as objective hair loss that patients may need to wear wigs and needed a few months to recover), hepatotoxicity (aspartate transaminase or alanine transaminase more than 2 times up the normal limit), flu-like symptoms (fever, headache, myalgia, and arthralgiaetc), gastrointestinal side effects (stomach ache, diarrhea, reduced appetite, nausea, and vomiting) and pancreatitis (abdominal pain with evaluated amylase). 23 Complete blood counts were required once a week in the first 2-month on thiopurines, then twice a month later. The primary endpoint was leukopenia. The secondary endpoint was drug withdrawal for other reasons, including other adverse events, ineffectiveness, etc. Other regular laboratory measurements regarding adverse events and efficacy were also collected at every visit (twice a week in the first month and once a month later). The average dose of thiopurines was calculated from the final dose of the patients who could continue thiopurines for more than 6 months.
Statistical Analyses
Statistic analysis and calculations were performed by SPSS 21.0 (SPSS Inc., Chicago, IL) and Prism 6 (GraphPad Software, La Jolla, CA). One-sample Quantitative variables were expressed as median and range. Categorical variables were compared using method x 2 or Fisher test. A nonparametric Kruskal-Wallis H-test was used to evaluate the difference among independent groups. Logistic regression analyses were performed to identify the associations of leukopenia with candidate variant and the relevant factors. Receiver operating characteristic curve was obtained to plot the sensitivity and specificity for NUDT15 genotypes to predict the development of leukopenia. Haploview 4.2 was used to determine the deviation from the Hardy-Weinberg equilibrium. P value less than 0.05 was considered statistically significant.
RESULTS
Clinical Characteristics of IBD Patients
A total of 732 IBD patients were enrolled. Among them, 692 were treated on AZA, whereas 40 were on mercaptopurines. The median age was 28 (4-68) years. The median dosage of AZA was 1.5 (range: 0.3-3.3) mg$kg 21 $d 21 . Leukopenia was observed in 177 patients (24.2%) during the follow-up. The baseline characteristics of the patients are summarized in Table 1. NUDT15 c.415C.T, c.36_37insGGAGTC, c.52G.A, and TPMT 719A.G genotype distributions were in Hardy-Weinberg equilibrium (P . 0.05) (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B508). Although TPMT*2, TPMT*3A, and TPMT*3B alleles were not observed in our cohort. Of the 732 subjects analyzed, the mutant allelic frequency of NUDT15 c.415C.T, c.36_37insGGAGTC, and c.52G.A were 12.7%, 5.8%, and 1.2%, respectively. The 2 NUDT15 polymorphisms, c.415C.T and c.36_37insGGAGTC, were found to be in strong linkage disequilibrium pattern (D 0 ¼ 0.69, r 2 ¼ 0.20). According to Takaya et al, 22 we inferred NUDT15 c.415C.T, c.36_37insGGAGTC, c.52G.A as haplotypes *3, *5, and *6, respectively. In particular, the presence of both NUDT15 c.415C.T and c.36_37insGGAGTC variants was defined as the haplotype *2. In our research, we found totally 9 kinds of NUDT15 diplotypes and the frequency of each diplotype were listed in Table 2 , Supplemental Digital Content 1, http://links. lww.com/IBD/B508. The allelic frequency of TPMT 719A.G was 1.6% (see Table 1 , Supplemental Digital Content 1, http:// links.lww.com/IBD/B508).
Association of NUDT15/TPMT Genotypes with Leukopenia
Associations between thiopurine-induced leukopenia and NUDT15/TPMT genotypes were listed in Table 2 . There were significant associations of NUDT15 c.415C.T, c.36_37insGGAGTC, and c.52G.A with thiopurine-induced leukopenia (P ¼ 1.81 · 10 220 , P ¼ 4.74 · 10 28 , and P ¼ 0.04, respectively) ( Table 2) . Compared with the wide type homozygotes, patients carrying variant alleles (NUDT15 c.415C.T, c.36_37insGGAGTC, and c.52G.A) have much higher risk for leukopenia with the OR and 95% confidence interval (CI) as 4.45 (3.23-6.12), 3.52 (2.26-5.49), and 2.83 (1.08-7.39), respectively. However, TPMT genotypes showed no significant relevance with leukopenia in this cohort (P ¼ 0.25) ( Table 2) .
Further, we investigated the prevalence of leukopenia between different NUDT15 diplotypes. Not only all of the homozygotes carrying NUDT15 c.415C.T (NUDT15*2/*3, *3/ *3), but also the heterozygous carrying both c.415C.T and c.52G.A (NUDT15*2/*3) developed early leukopenia (100%, 15/15). As for the heterozygous carriers of *1/*2, *1/*3, *1/*5, and *1/*6, the frequency of leukopenia were 49.1%, 42.2%, 30.8%, and 35.0%, respectively, whereas only 15.1% for wildtype carriers (*1/*1) (Table 3) .
When comparing NUDT15 c.415C.T, c.36_37insGGAGTC, and c.52G.A genotypes among different grades of leukopenia; we found that NUDT15 c.415C.T and c.36_37insGGAGTC were associated with all grades of leukopenia (P # 0.001) ( Table 4) . While NUDT15 c.52G.A was only associated with grade 3 and grade 4 leukopenia (P ¼ 0.01) ( Table 4) .
As comparing the NUDT15 c.415C.T, c.36_37insGGAGTC, c.52G.A genotypes among different phases of leukopenia, we found that NUDT15 c.415C.T and c.36_37insGGAGTC were associated with both early and late leukopenia (P # 0.001). Although NUDT15 c.52G.A was only associated with early leukopenia (P ¼ 0.004), no association was found in late leukopenia. Detailed data were shown in Table 5 .
Multivariate Analysis of ThiopurineInduced Leukopenia
Univariate analysis showed that sex and NUDT15 c.415C.T, c.36_37insGGAGTC, c.52G.A were risk factors for thiopurine-induced leukopenia, whereas thiopurine dosage, disease type, age prescribed on thiopurines, and concomitant therapy were not associated with the risk for leukopenia (Table 6 ). Multivariate logistic regression further confirmed that female patients (OR 2.80, 95% CI, 1.90-4.13) and patients with NUDT15 c.415C.T (OR 4.54, 95% CI, 3.02-6.80), c.52G.A genotypes (OR 4.63, 95% CI, 1.65-13.00) were at higher risk for leukopenia (Table 6 ). The NUDT15 c.415C.T had a sensitivity of 49.2% (87/177) and specificity of 84.1% (467/555) for predicting leukopenia, with area under the curve (AUC) of 0.67. After combined analyses of NUDT15 c.415C.T, c.36_37insGGAGTC, and c.52G.A, the sensitivity increased to 55.4%, with an AUC of 0.69. The specificity, positive predictive value, and negative predictive value for leukopenia were 80.2%, 47.1%, and 84.9% ( Fig. 1 and see Table 3 , Supplemental Digital Content 1, http://links.lww.com/IBD/B508). Although only a slight increase in AUC after combined detection, we found that the 2 additional variants were useful in predicting leukopenia in NUDT15 c.415C.T wild-type and heterozygotes. There were associations between c.36_37insGGAGTC and leukopenia in both subgroups of c.415C.T wide type (n ¼ 557) and c.52G.A wide type (n ¼ 715) ([P ¼ 0.026; odds ratio, 2.95; 95% CI, 1.14-7.90], [P ¼ 6.69 · 10 29 ; odds ratio, 3.96; 95% CI, 2.49-6.30], respectively), suggesting a potential predictive role of 36_37insGGAGTC in NUDT c.415C.T and c.52G.A widetype. Notably, all the heterozygotes both carrying c.415C.T and c.52G.A developed early leukopenia (100%, 4/4).
Median Dosage of Thiopurines Was Lower in NUDT15 Mutant Carriers
We compared the median dosage of patients with thiopurine therapy for more than 6 months to reflect influence of NUDT15 genotypes to tolerant dosage, as differences may exist among the included centers concerning the scheduling of thiopurine usage. A total of 405 subjects were included. The median dosage of patients with NUDT15*1/*1 genotype was (1. (Fig. 2) . However, there was no difference between NUDT15*1/*1 and *1/*5 (P ¼ 0.31) and *1/*6 (P ¼ 0.19) genotype carriers.
DISCUSSION
The incidence of thiopurine-induced leukopenia is more common in Asians than in Caucasians, which is challenging Asian physicians to prescribe thiopurines for patients with IBD. On contrary to approximately 5% in Caucasians, approximately 20% Asians develop thiopurine-induced leukopenia at a medium AZA dosage less than 2 mg$kg 21 $d 21 , 20,21,24 more frequent and severe leukopenia is likely to happen with standard doses of thiopurines in this population. As a result, the clinical trials and the Asian-Pacific consensus recommended a lower starting dose in Asian compared with Caucasian populations along with close monitoring of complete blood count and 1-1.5 mg$kg 21 $d 21 was suggested. 25, 26 In our present multicenter retrospective study, the rate of leukopenia was 24.2% with the median dosage of 1.5 mg$kg 21 NUDT15 is an enzyme member of nudix hydrolyses enzyme family, which consists mainly of pyrophosphohydrolases that act on nucleoside diphosphatates. The function of this enzyme is hydrolyzing the thiopurine effector metabolites 6-thio-deoxy-GTP (dGTP) and 6-thio-GTP, thereby limiting the efficacy of thiopurines. 22, 27 The association of NUDT15 c.415C.T variant and thiopurine-induced leukopenia was first discovered in a Korean IBD cohort in 2014 by GWAS. 21 This was later verified in Japanese IBD population. Takeya et al 22 in 2016 showed that NUDT15 coding variants (c.415C.T, c.415C.T, c.36_37insGGAGTC, and c.52G.A) that resulted in 74.4%-100% loss of nucleotide diphosphatase activity. Thus loss-of-function NUDT15 diplotypes were consistently associated with thiopurine intolerance across the children with acute lymphoblastic leukemia (P , 0.05).
In present study, we further confirmed the findings of our previous single-center study that NUDT15 c.415C.T is better than TPMT as a predictor of risk for thiopurine-induced leukopenia in Chinese patients with IBD. 19 The rate of leukopenia was 100% in homozygotes and increased to around 3-folds in heterozygotes of NUDT15 c.415C.T compared with the wild-type carriers. Furthermore, we reported here first that the other 2 newly coding variant (c.36_37insGGAGTC and c.52G.A) were associated with thiopurine-induced leukopenia in patients with IBD (Table 2) . Notably, we found that not only NUDT15 c.415C.T homozygotes (*2/*3, *3/*3), but also the heterozygous carrying both c.415C.T and c.52G.A (*3/*5) developed early leukopenia (100%, 15/15), suggesting that detection of c.52G.A could help to distinguish early leukopenia in c.415C.T heterozygotes ( Table 3 ). The rate of leukopenia was 100% in c.36_37insGGAGTC homozygotes, but the frequency is only 0.1%. In addition, we found that NUDT15 c.415C.T and c.36_37insGGAGTC were associated with all phases of leukopenia and all grades of leukopenia (P # 0.001), whereas NUDT15 c.52G.A was only associated with early and sever (grade3/4) leukopenia (P ¼ 0.004) (Table 4) . Thus, not only NUDT15 c.415C.T but also NUDT15 c.36_37insGGAGTC and c.52G.A are useful for predicting thiopurine-induced leukopenia in Chinese patients with IBD.
TPMT is a major enzyme for inactivation of thiopurines. Individual carrying TPMT variants with deficient enzyme activity accumulated much more 6-TGN, which leads to a greater risk of leukopenia. 28 However, the frequency of TPMT mutant alleles was much lower in Asian populations, as our study showed a prevalence of 1.8%. In our study, heterozygous mutant allele (TPMT *1/*3C) was found in 27 individuals (3.1%), and only 2.3% (4/ 177) individuals experiencing leukopenia carried variant TPMT alleles (Table 2) . It is widely known that patients who are treated with thiopurines require a dosage reduction if they are heterozygous with a TPMT nonfunctional allele (*2, *3A, *3C, etc) and these TPMT heterozygous patients can usually be treated with ;50% of the standard dosage. 29 In our study, the dosage of AZA for TPMT heterozygosis was 1.6 (0.6-2.3) mg$kg 21 $d 21 , which was already a lower dose. Thus, it may be one of the reasons that TPMT was not associated with leukopenia in this study. Moreover, the studies in Japan 13 and Korea 21 together with our data demonstrated that TPMT mutations could just responsible for very small part (;3%) of leukopenia because of the low frequency of TPMT*3C. Thus, the clinical value of predicting leukopenia by testing TPMT genotype in Asian was limited. In our study, the Logistic analysis showed that women and NUDT15 variants (c.415 C.T and c.52G.A) except c.36_37insGGAGTC were risk factors for thiopurine-induced leukopenia (Table 6 ). The relationship of sex and thiopurine-induced leukopenia has been reported in previous studies including our single-center study, which could possibly be explained by a significantly lower TPMT activity in women as compared with men. [30] [31] [32] Meanwhile, drug clearance in general is lower in women and tends to decrease with age in both sexes, which is the most likely explanation for these findings. However, NUDT15 c.36_37insGGAGTC was dropped out of multivariate analysis statically (P ¼ 0.067), a larger sample size may be needed to prove these associations. In addition, we analyzed the effect of c.36_37insGGAGTC on leukopenia after excluding c.415C.T and c.52G.A, we found that there were associations between c.36_37insGGAGTC and leukopenia in both subgroups of c.415C.T wide-type and c.52G.A wide-type, suggesting a potential predictive role of c.36_37insGGAGTC in NUDT c.415C.T and c.52G.A wide-type.
More importantly, combined detection of the variants of NUDT15 c.36_37insGGAGTC and c.52G.A with c.415C.T increased the sensitivity from 49.2% to 55.4%, suggesting that combined analysis will predict additional 5% patients who would experience leukopenia ( Fig. 1 and see Table 3 , Supplemental Digital Content 1, http://links.lww.com/IBD/B508). Although only a slight increase in AUC after combined detection, we found that the 2 additional variants were useful in predicting leukopenia in NUDT15 c.415C.T wild-type and heterozygotes. Notably, all the heterozygotes both carrying c.415C.T and c.52G.A developed early leukopenia. Thus, combined detection of NUDT15 c.415C.T, c.36_37insGGAGTC, and c.52G.A is a more comprehensive pharmacogenetic model for individualized thiopurine therapy. Considering the 100% rate of leukopenia in c.415C.T homozygotes and cost and effect, we recommended to detect the other 2 variants in c.415C.T heterozygous and wild-type carriers.
As a prospective study, differences may be existed concerning the scheduling of thiopurine usage. So we compared the median dosage between wide-type carriers (*1/*1) and other variant diplotypes (*1/*2, *1/*3, *1/*5, *1/*6) in subjects who are tolerant to thiopurines for more than 6 months to reflect the tendency of tolerant dosage. The median dosage of individuals with NUDT15*1/*1 (1. (Fig. 2) . Because the sample size of NUDT15 *1/*5 subgroups was small (n ¼ 7), the difference was not statistically significant, which might be type 2 errors in statistic analysis, further study needs to validate the dosage of NUDT15 *1/*5 in larger cohorts. Our study has some limitations. First, whether this monitoring strategy could reduce leukopenia and whether it might influence the efficacy remains unknown. Second, the mechanism underlying the NUDT15 variant leading to leukopenia was not clarified, including the function of NUDT15 gene-coded enzyme, the activity of the enzyme, and how does the variant influence the toxicity of thiopurines. Further prospective and functional studies needed to be done to clarify these questions.
In summary, we first confirmed that NUDT15 c.415C.T, c.36_37insGGAGTC, and c.52G.A variant were risk factors for thiopurine-induced leukopenia in Chinese patients with IBD. Therefore, NUDT15 c.415C.T is recommend to be detected before initiating thiopurine drugs in Chinese patients with IBD. In heterozygous or wide-type of c.415C.T, combination of c.36_37insGGAGTC and c.52G.A variant testing is useful to identify early leukopenia and increase predictive sensitivity. Dose monitoring by NUDT15 variants detection is promising in individualized therapy. 
